Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval By: CNBC.com News June 09, 2023 at 10:07 AM EDT Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment. Read More >> Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval By: CNBC.com News June 09, 2023 at 10:07 AM EDT Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment. Read More >>